ClinicalTrials.gg
CompletedNCT03660436Updated Dec 19, 2018

An Investigational Study of Experimental Medication BMS-986165 in Healthy Participants

A Phase 1 interventional study of BMS-986165 and MMF in Healthy Participants, sponsored by Bristol-Myers Squibb. Completed at 1 site in United States. Open to male participants aged 18 Years to 50 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2018-12-19.

Sponsored by Bristol-Myers Squibb · Phase 1, Interventional, and Treatment

From the registry’s dates

  • Primary completion was Oct 2018, 8 years 1 month ago, and no results have been posted to the registry.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
131
Allocation
Not applicable
Ages
18 Years to 50 Years
Sex
Male
01

Study summary

The purpose of this study is to investigate the effects of experimental medication BMS-986165 in healthy male participants.

02

Conditions studied

  • Healthy Participants
03

In context

Lead sponsor

Bristol-Myers Squibb is the lead sponsor of 1,561 studies on the registry; 118 are open to participants now.

Of its 436 completed or terminated interventional studies of FDA-regulated products, 228 (52%) have results posted.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 50 Years
Sexes eligible
Male
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

For more information regarding Bristol-Myers Squibb Clinical Trial participation, please visit www.BMSStudyConnect.com

Inclusion criteria

Inclusion Criteria:

  • Healthy participant, as determined by no deviation from normal in physical examination, (ECGs), and clinical laboratory determinations
  • of 18.0 to 32.0 kg/m2, inclusive, and weight ≥ 50 kg, at screening
  • Normal renal function at screening as evidenced by an estimated (glomerular filtration rate) > 80 mL/min/1.732 m2

Exclusion criteria

Exclusion Criteria:

  • Any medical condition that presents a potential risk to the participant and/or may compromise the objectives of the study, including a history of or active liver disease
  • Positive anti- John Cunningham virus (JCV) antibody test at Screening
  • History of allergy to MMF, BMS-986165, related compounds or any significant drug allergy

Other protocol defined inclusion/exclusion criteria could apply

Terms in these criteria, in plain language(4)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

GFR and eGFR (kidney filtering)

GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².

Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
131 participants (actual)

Study arms

  • Experimental
    BMS-986165 + MMF

    Oral administration

    Drug: BMS-986165 · Drug: MMF

Interventions

  • Specified dose on specified days

  • DrugMMF

    Specified dose on specified days

    Also known as: Mycophenolate Mofetil

06

What researchers measure

Primary outcomes

  1. Maximum plasma concentration (Cmax) of mycophenolic acid (MPA)

    Time frame: 18 days

  2. Area under the concentration vs time curve from time zero to the last quantifiable plasma concentration (AUC[0-T]) of MPA

    Time frame: 18 days

  3. AUC extrapolated to infinity (AUC[INF]) of MPA

    Time frame: 18 days

Secondary outcomes

  1. Number of adverse events (AE)

    Time frame: Up to 48 days

  2. Number of serious adverse events (SAE)

    Time frame: Up to 48 days

  3. Number of AEs leading to discontinuation

    Time frame: Up to 48 days

  4. Incidence of clinically significant changes in laboratory test results, vital sign measurements, electrocardiograms (ECGs) and physical examination results

    Time frame: 18 days

07

Study locations

1 site
  • PRA Health Sciences
    Salt Lake City, Utah 84107, United States
08

References and documents

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Aug 2018 to primary completion in Oct 2018, 1 month.

How these figures are worked out, and which studies are left out of them.

Registered
Sep 4, 2018
First posted
Sep 6, 2018
StartActual
Aug 14, 2018
Primary completionActual
Oct 10, 2018
CompletionActual
Oct 18, 2018
Last update
Dec 19, 2018
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Dec 19, 2018, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT03660436
Responsible party
Sponsor
First posted
Sep 6, 2018
Start date
Aug 14, 2018
Primary completion
Oct 10, 2018
Completion
Oct 18, 2018
Last update
Dec 19, 2018

Study contacts

Bristol-Myers Squibb
study director · Bristol-Myers Squibb

Oversight

FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Dec 2018. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Deucravacitinib

Start the discussion